Renal impairment: Not recommended in patients with CrCl
is subject to variability due to a number of causes including acute and chronic disease, it is reported that this method is not very sensitive for GFR (21).
at least daily in patients with changing renal function and adjust the dose of Zerbaxa accordingly.
Among those with AKI most of them 42/49 were with Crcl
from 60-89ml/min, 5/49 were with creatinine clearance between 30-59ml/minute and only two were with clearance below 30 ml/min.
The significant preoperative factors, from univariate analysis, were male gender, weight, BMI, preoperative ROM, platelet count, CrCl
, albumin, and large prosthesis (p < 0.015 all) (Table 2).
Elior Group (Paris:ELIOR), an operator in the contracted food industry, announced on Monday that it has entered the Indian market with the simultaneous acquisitions of MegaBite Food Services and CRCL
, two leading contract caterers for the business & industry market.
The recommended dose of cetirizine is 5 mg/day for adults and children age 12 years or older with moderate to severe kidney dysfunction (CrCl
11 to 31 mL/minute), or on dialysis (Pfizer, Inc., 2002).
The Cockcroft Gault's CrCl
formula was developed in 1976 by using the mean 24-hour urine creatinine excretion from two urine collections obtained in 249 adult men aged from 18 to 92 years.
[7,20] The SA 2010 ART guidelines recommended measurement of the serum creatinine concentration before treatment initiation, at 3, 6 and 12 months after initiation and then annually, with calculation of creatinine clearance (CrCl
) using the Cockcroft-Gault formula.
Apixaban, rivaroxaban and edoxaban are not recommended in patients with CrCl
<15 ml/min, and dabigatran is contraindicated in patients with CrCl
<30 ml/min (13,15,17,19).
2014 PHASE 1 End date: May 2014 Website: www.ClinicalTrials.gov Dabigatran Drug Name: Idarucizumab Clinical Trial#: NCT02104947 Start Date: May 2014 PHASE III End date: July 2017 Website: www.ClinicalTrials.gov Edoxaban Drug Name:Aripazine (Ciraparantag) Clinical Trial#: NCTO1826266 Start Date: July 2013 PHASE 1 End Date: December 2013 Website: www.ClinicalTrials.gov Rivaroxaban Drug Name: Andexanet Alfa Clinical Trial#: NCT02220725 Start Date: May 2014 PHASE III End Date: December 2014 Website: www.ClinicalTrials.gov Abbreviations: CrCl
= creatinine clearance; DVT = deep vein thrombosis; FDA = Federal Drug Administration; INR = international normalized ratio; NVAF = nonvalvular atrial fibrillation; PE = pulmonary embolus;VTE = venous thromboembolism.
Because the new estimated glomerular filtration (GFR)  rate equations, such as Modification of Diet in Renal Diseaseisotope dilution mass spectrometry (MDRD-IDMS) or CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration), are not included in the software, estimations for dose adjustment were carried out using the creatinine clearance (CrCl
) calculated by the Cockcroft-Gault (CG) formula.